# Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)

Study · id `cardio:ct-nct07462260` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07462260](<https://clinicaltrials.gov/study/NCT07462260>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07462260

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT07462260. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-01 (actual); primary completion 2026-09-23 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT07462260, source copy `cardio:ctgov-nct07462260-2026-09-24`, retrieved 2026-10-31)
- Started: 2025-08-01 (actual) (ClinicalTrials.gov record NCT07462260, source copy `cardio:ctgov-nct07462260-2026-09-24`, retrieved 2026-10-31)
- Primary completion: 2026-09-23 (actual) (ClinicalTrials.gov record NCT07462260, source copy `cardio:ctgov-nct07462260-2026-09-24`, retrieved 2026-10-31)
- Completion: 2026-09-23 (actual) (ClinicalTrials.gov record NCT07462260, source copy `cardio:ctgov-nct07462260-2026-09-24`, retrieved 2026-10-31)
- Countries: Pakistan (ClinicalTrials.gov record NCT07462260, source copy `cardio:ctgov-nct07462260-2026-09-24`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07462260-2026-09-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)
- Acronym: SERIES
- Condition: Pulmonary Hypertension
- Condition: Rheumatic Valvular Heart Disease
- Intervention (Drug): Sildenafil 25 MG
- Intervention (Drug): Placebo
- Lead sponsor: Sindh Institute of Cardiovascular Diseases
- Lead sponsor class: OTHER
- Collaborator: National Institute of Cardiovascular Diseases
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)

## Provenance

Content hash: e4d39928d281e57ab892aecd3a38932feab25847ccdf6a9ca5eb2e658e42be19
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
